Pyxis Oncology
PYXS
101 hedge funds and large institutions have $190M invested in Pyxis Oncology in 2026 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 13 closing their positions.
1,866% more capital inflows, than outflows
Capital inflows: $146M | Capital outflows: $7.42M
379% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $253K
200% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 13
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
72.02% more ownership
Funds ownership: 53.91% → 125.92% (+72%)
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
33% more funds holding
Funds holding: 76 → 101 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$35.8M |
| 2 |
OrbiMed
New York
|
+$25.3M |
| 3 |
RTW Investments
New York
|
+$19.7M |
| 4 |
GordonMD Global Investments
Beverely Hills,
California
|
+$16.7M |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$5.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
-$1.58M |
| 2 |
Renaissance Technologies
New York
|
-$1.22M |
| 3 |
HealthInvest Partners
Stockholm,
Sweden
|
-$916K |
| 4 |
Jane Street
New York
|
-$779K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$380K |
PYXS Hedge Fund Activity: Q3 2026 in Review
101 of the 8,154 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2026, worth a combined $190M — up 88% from $101M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PYXS positions and 13 closed out — a net gain of 26 holders — while 26 added to existing stakes and 19 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $35.8M. The largest seller was Woodline Partners, exiting entirely with an estimated $1.58M sold.
- 101 institutional investors held Pyxis Oncology (PYXS) as of Q3 2026, up from 76 in Q2 2026.
- Funds reported $190M of Pyxis Oncology stock for Q3 2026, up 88% quarter-over-quarter.
- 39 funds opened new Pyxis Oncology positions in Q3 2026 and 13 closed out, a net change of +26 holders.
- The largest Pyxis Oncology buyer in Q3 2026 was BVF Inc, an estimated $35.8M added.
- The largest Pyxis Oncology seller in Q3 2026 was Woodline Partners, an estimated $1.58M sold.
Based on aggregated 13F filings for Q3 2026.